Business Context and Reporting Period
Company: SeaStar Medical Holding Corp
Filing Type: Form 8-K (Current Report)
Date of Report: October 3, 2023
Reporting Period: Event-based (October 3, 2023)
This filing reports a material event under Item 8.01 Other Events. The Company disclosed communications received from the U.S. Food and Drug Administration (FDA) regarding its Humanitarian Device Exemption (HDE) application for its pediatric Selective Cytopheretic Device (SCD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is an event disclosure and does not contain financial statements or performance metrics.
Material Changes
No financial material changes versus a prior comparable period are reported in this document. The material change is regulatory in nature, specifically the receipt of FDA communications concerning the pediatric SCD HDE application.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the FDA communications. Specific content of the FDA feedback is not detailed in the 8-K text itself.
- Risks and Contingencies: The outcome of the HDE application process represents a key contingency for the Company's pediatric SCD product line. Regulatory delays or adverse communications could impact the timeline for market approval.
- Unusual Items: None reported beyond the regulatory event.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific details on the FDA's feedback regarding the pediatric SCD HDE application.
- Verify the current status of the HDE application on the FDA database to assess potential approval timelines.
- Monitor subsequent filings for any updates on the regulatory review process or changes to the Company's product development strategy.